{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:09:51Z","timestamp":1770329391293,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T11:49:20Z","timestamp":1630064960000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-8901","authenticated-orcid":false,"given":"Daniel Silva","family":"Nogueira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds Alberto de P\u00e1dua Covas","family":"Lage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hebert Fabr\u00edcio","family":"Culler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.08.004_bib0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood Journal"},{"key":"10.1016\/j.clml.2021.08.004_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.clml.2021.08.004_bib0004","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3324\/haematol.11502","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"92","author":"Federico","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.004_bib0005","first-page":"426","article-title":"Prognostic significance of follicular lymphoma international prognostic index 2 (FLIPI2) in follicular lymphoma patients treated with rituximab maintenance","volume":"25","author":"Xu","year":"2017","journal-title":"hongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2021.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3324\/haematol.11502","article-title":"Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study","volume":"92","author":"Federico","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.004_bib0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5045\/br.2014.49.3.148","article-title":"Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor","volume":"49","author":"Yoo","year":"2014","journal-title":"Blood Res"},{"key":"10.1016\/j.clml.2021.08.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP\u2013 rituximab versus CHOP \u00fe 131Iodine\u2014Tositumomab","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0012","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Evaluation of the different stratification models for POD24 prediction in patients with follicular lymphoma","author":"Wu","year":"2020"},{"key":"10.1016\/j.clml.2021.08.004_bib0013","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular lymphoma evaluation index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0014","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.004_bib0015","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","article-title":"Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation","volume":"9","author":"Yang","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.clml.2021.08.004_bib0017","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0019","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","article-title":"Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2","volume":"103","author":"Horn","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.004_bib0021","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.004_bib0022","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/asheducation-2017.1.358","article-title":"Follicular lymphoma: are we ready for a risk-adapted approach?","author":"Kahl","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.08.004_bib0023","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after firstline therapy in patients with follicular lymphoma: a pooled analysis of central scan re- view in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0024","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume pre- dicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0025","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0026","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood J"},{"key":"10.1016\/j.clml.2021.08.004_bib0027","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0028","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.08.004_bib0029","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line immunochemotherapy and antibody maintenance in the phase iii GALLIUM study","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0030","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0031","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The international harmonization project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2021.08.004_bib0032","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.08.004_bib0034","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1080\/10428194.2020.1786554","article-title":"Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome","volume":"61","author":"Bitansky","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.004_bib0035","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clml.2021.08.004_bib0036","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0037","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0038","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/hon.2438_91","article-title":"POD24 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage follicular lymphoma enrolled in the FOLL05 trial by FIL","volume":"35","author":"Luminari","year":"2017","journal-title":"Haematol Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0039","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bjh.17138","article-title":"Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma","volume":"193","author":"Mozas","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.08.004_bib0040","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0041","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe D'Etude des lymphomes folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0042","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2019-129294","article-title":"The \u2018real world\u2019 uptake and prognostic impact of GELF in newly diagnosed follicular lymphoma: an australasian alliance initiative","volume":"134","author":"Barraclough","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0043","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.004_bib0044","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The minimal residual disease in non-hodgkin's lymphomas: from the laboratory to the clinical practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.08.004_bib0045","article-title":"Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era?","volume":"9","author":"Gritti","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2021.08.004_bib0046","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.08.004_bib0047","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients","volume":"132","author":"Pott","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0048","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.004_bib0049","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.08.004_bib0050","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.clml.2021.08.004_bib0051","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/HS9.0000000000000214","article-title":"Novel prognostic tools that identify high-risk follicular lymphoma","volume":"3","author":"Luminari","year":"2019","journal-title":"HemaSphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:37Z","timestamp":1761871177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021003633"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}